NCT07758634 A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
| NCT ID | NCT07758634 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | CRISPR Therapeutics AG |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 69 participants |
| Start Date | 2026-09-25 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 69 participants in total. It began in 2026-09-25 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Study of CTX340 in Participants with Uncontrolled Hypertension.
Eligibility Criteria
Key Inclusion Criteria: 1. Age: ≥18 and ≤75 years. 2. Body mass index ≤40 kg/m2. 3. 24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment 4. Be on treatment with ≥4 antihypertensive therapies at effective doses, of which ≥1 must be a diuretic. 5. Participants who at any point had childbearing potential must currently be postmenopausal 6. All participants capable of producing sperm must agree to the use of an acceptable method of effective contraception and their partners with childbearing potential should also agree to use an effective method of contraception. Exclusion Criteria: 1. Serum aldosterone and direct renin concentration (or plasma renin activity \[PRA\]) suggestive of primary aldosteronism 2. Mean diastolic blood pressure (DBP) ≤65 mm Hg on screening ABPM. 3. Participants with vascular cause of hypertension which may be amendable to revascularization 4. Participants with treatable/reversible causes of uncontrolled hypertension 5. History of renal artery denervation within past 12 months. 6. Orthostatic hypotension 7. Complete blood count (CBC) outside the specified ranges per protocol. 8. Evidence of liver disease 9. History of a significant coagulation disorder. 10. Uncontrolled or untreated thyroid disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07758634 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07758634 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07758634 currently recruiting?
Yes, NCT07758634 is actively recruiting participants. Contact the research team at medicalaffairs@crisprtx.com for enrollment information.
Where is the NCT07758634 trial being conducted?
This trial is being conducted at Jacksonville, United States, Orlando, United States, Port Orange, United States, Rochester, United States and 7 additional locations.
Who is sponsoring the NCT07758634 clinical trial?
NCT07758634 is sponsored by CRISPR Therapeutics AG. The trial plans to enroll 69 participants.